Literature DB >> 22653792

Accurate differentiation of recurrent gliomas from radiation injury by kinetic analysis of α-11C-methyl-L-tryptophan PET.

Bálint Alkonyi1, Geoffrey R Barger, Sandeep Mittal, Otto Muzik, Diane C Chugani, Gautam Bahl, Natasha L Robinette, William J Kupsky, Pulak K Chakraborty, Csaba Juhász.   

Abstract

UNLABELLED: PET of amino acid transport and metabolism may be more accurate than conventional neuroimaging in differentiating recurrent gliomas from radiation-induced tissue changes. α-(11)C-methyl-l-tryptophan ((11)C-AMT) is an amino acid PET tracer that is not incorporated into proteins but accumulates in gliomas, mainly because of tumoral transport and metabolism via the immunomodulatory kynurenine pathway. The aim of this study was to evaluate the usefulness of (11)C-AMT PET supplemented by tracer kinetic analysis for distinguishing recurrent gliomas from radiation injury.
METHODS: Twenty-two (11)C-AMT PET scans were obtained in adult patients who presented with a lesion suggestive of tumor recurrence on conventional MRI 1-6 y (mean, 3 y) after resection and postsurgical radiation of a World Health Organization grade II-IV glioma. Lesional standardized uptake values were calculated, as well as lesion-to-contralateral cortex ratios and 2 kinetic (11)C-AMT PET parameters (volume of distribution [VD], characterizing tracer transport, and unidirectional uptake rate [K]). Tumor was differentiated from radiation-injured tissue by histopathology (n = 13) or 1-y clinical and MRI follow-up (n = 9). Accuracy of tumor detection by PET variables was assessed by receiver-operating-characteristic analysis.
RESULTS: All (11)C-AMT PET parameters were higher in tumors (n = 12) than in radiation injury (n = 10) (P ≤ 0.012 in all comparisons). The lesion-to-cortex K-ratio most accurately identified tumor recurrence, with highly significant differences both in the whole group (P < 0.0001) and in lesions with histologic verification (P = 0.006); the area under the receiver-operating-characteristic curve was 0.99. A lesion-to-cortex K-ratio threshold of 1.39 (i.e., a 39% increase) correctly differentiated tumors from radiation injury in all but 1 case (100% sensitivity and 91% specificity). In tumors that were high-grade initially (n = 15), a higher lesion-to-cortex K-ratio threshold completely separated recurrent tumors (all K-ratios ≥ 1.70) from radiation injury (all K-ratios < 1.50) (100% sensitivity and specificity).
CONCLUSION: Kinetic analysis of dynamic (11)C-AMT PET images may accurately differentiate between recurrent World Health Organization grade II-IV infiltrating gliomas and radiation injury. Separation of unidirectional uptake rates from transport can enhance the differentiating accuracy of (11)C-AMT PET. Applying the same approach to other amino acid PET tracers might also improve their ability to differentiate recurrent gliomas from radiation injury.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22653792      PMCID: PMC3777234          DOI: 10.2967/jnumed.111.097881

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  40 in total

Review 1.  A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors.

Authors:  W Hollingworth; L S Medina; R E Lenkinski; D K Shibata; B Bernal; D Zurakowski; B Comstock; J G Jarvik
Journal:  AJNR Am J Neuroradiol       Date:  2006-08       Impact factor: 3.825

2.  Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas.

Authors:  Walter Rachinger; Claudia Goetz; Gabriele Pöpperl; Franz Josef Gildehaus; Friedrich Wilhelm Kreth; Markus Holtmannspötter; Jochen Herms; Walter Koch; Klaus Tatsch; Jörg-Christian Tonn
Journal:  Neurosurgery       Date:  2005-09       Impact factor: 4.654

3.  18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.

Authors:  Wei Chen; Daniel H S Silverman; Sibylle Delaloye; Johannes Czernin; Nirav Kamdar; Whitney Pope; Nagichettiar Satyamurthy; Christiaan Schiepers; Timothy Cloughesy
Journal:  J Nucl Med       Date:  2006-06       Impact factor: 10.057

4.  In vivo uptake and metabolism of alpha-[11C]methyl-L-tryptophan in human brain tumors.

Authors:  Csaba Juhász; Diane C Chugani; Otto Muzik; Dafang Wu; Andrew E Sloan; Geoffrey Barger; Craig Watson; Aashit K Shah; Sandeep Sood; Eser L Ergun; Tom J Mangner; Pulak K Chakraborty; William J Kupsky; Harry T Chugani
Journal:  J Cereb Blood Flow Metab       Date:  2006-03       Impact factor: 6.200

Review 5.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

6.  Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells.

Authors:  Keiichi Kobayashi; Akiko Ohnishi; Jutabha Promsuk; Saki Shimizu; Yoshikatsu Kanai; Yoshiaki Shiokawa; Motoo Nagane
Journal:  Neurosurgery       Date:  2008-02       Impact factor: 4.654

7.  Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma.

Authors:  Gabriele Pöpperl; Claudia Götz; Walter Rachinger; Franz-Josef Gildehaus; Jörg-Christian Tonn; Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-10       Impact factor: 9.236

8.  Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging.

Authors:  Qing-Shi Zeng; Chuan-Fu Li; Hong Liu; Jun-Hui Zhen; De-Chao Feng
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-02-07       Impact factor: 7.038

9.  Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?

Authors:  Gabriele Pöpperl; Friedrich W Kreth; Jochen Herms; Walter Koch; Jan H Mehrkens; Franz J Gildehaus; Hans A Kretzschmar; Jörg C Tonn; Klaus Tatsch
Journal:  J Nucl Med       Date:  2006-03       Impact factor: 10.057

Review 10.  Metabolic and molecular imaging in neuro-oncology.

Authors:  Karl Herholz; David Coope; Alan Jackson
Journal:  Lancet Neurol       Date:  2007-08       Impact factor: 44.182

View more
  27 in total

1.  Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma.

Authors:  Edit Bosnyák; Sharon K Michelhaugh; Neil V Klinger; David O Kamson; Geoffrey R Barger; Sandeep Mittal; Csaba Juhász
Journal:  Clin Nucl Med       Date:  2017-05       Impact factor: 7.794

2.  Tryptophan PET predicts spatial and temporal patterns of post-treatment glioblastoma progression detected by contrast-enhanced MRI.

Authors:  Edit Bosnyák; David O Kamson; Natasha L Robinette; Geoffrey R Barger; Sandeep Mittal; Csaba Juhász
Journal:  J Neurooncol       Date:  2015-10-29       Impact factor: 4.130

3.  Radiation injury vs. recurrent brain metastasis: combining textural feature radiomics analysis and standard parameters may increase 18F-FET PET accuracy without dynamic scans.

Authors:  Philipp Lohmann; Gabriele Stoffels; Garry Ceccon; Marion Rapp; Michael Sabel; Christian P Filss; Marcel A Kamp; Carina Stegmayr; Bernd Neumaier; Nadim J Shah; Karl-Josef Langen; Norbert Galldiks
Journal:  Eur Radiol       Date:  2016-11-16       Impact factor: 5.315

4.  Clinical significance of tryptophan metabolism in the nontumoral hemisphere in patients with malignant glioma.

Authors:  David O Kamson; Tiffany J Lee; Kaushik Varadarajan; Natasha L Robinette; Otto Muzik; Pulak K Chakraborty; Michael Snyder; Geoffrey R Barger; Sandeep Mittal; Csaba Juhász
Journal:  J Nucl Med       Date:  2014-09-04       Impact factor: 10.057

5.  Increased tryptophan uptake on PET has strong independent prognostic value in patients with a previously treated high-grade glioma.

Authors:  David O Kamson; Sandeep Mittal; Natasha L Robinette; Otto Muzik; William J Kupsky; Geoffrey R Barger; Csaba Juhász
Journal:  Neuro Oncol       Date:  2014-03-26       Impact factor: 12.300

6.  Assessment of Tryptophan Uptake and Kinetics Using 1-(2-18F-Fluoroethyl)-l-Tryptophan and α-11C-Methyl-l-Tryptophan PET Imaging in Mice Implanted with Patient-Derived Brain Tumor Xenografts.

Authors:  Sharon K Michelhaugh; Otto Muzik; Anthony R Guastella; Neil V Klinger; Lisa A Polin; Hancheng Cai; Yangchun Xin; Thomas J Mangner; Shaohui Zhang; Csaba Juhász; Sandeep Mittal
Journal:  J Nucl Med       Date:  2016-10-20       Impact factor: 10.057

7.  Molecular imaging correlates of tryptophan metabolism via the kynurenine pathway in human meningiomas.

Authors:  Edit Bosnyák; David O Kamson; Anthony R Guastella; Kaushik Varadarajan; Natasha L Robinette; William J Kupsky; Otto Muzik; Sharon K Michelhaugh; Sandeep Mittal; Csaba Juhász
Journal:  Neuro Oncol       Date:  2015-06-18       Impact factor: 12.300

8.  Boron Accumulation in Brain Tumor Cells through Boc-Protected Tryptophan as a Carrier for Boron Neutron Capture Therapy.

Authors:  Chun-Ming Chio; Ying-Cheng Huang; You-Cheng Chou; Fu-Chun Hsu; Yen-Buo Lai; Chung-Shan Yu
Journal:  ACS Med Chem Lett       Date:  2020-03-16       Impact factor: 4.345

9.  In vivo metabolism of tryptophan in meningiomas is mediated by indoleamine 2,3-dioxygenase 1.

Authors:  Ian M Zitron; David O Kamson; Sam Kiousis; Csaba Juhász; Sandeep Mittal
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

10.  Amino Acid PET Imaging of the Early Metabolic Response During Tumor-Treating Fields (TTFields) Therapy in Recurrent Glioblastoma.

Authors:  Edit Bosnyák; Geoffrey R Barger; Sharon K Michelhaugh; Natasha L Robinette; Alit Amit-Yousif; Sandeep Mittal; Csaba Juhász
Journal:  Clin Nucl Med       Date:  2018-03       Impact factor: 7.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.